Details for New Drug Application (NDA): 214952
✉ Email this page to a colleague
NDA 214952 describes LIQREV, which is a drug marketed by Cmp Dev Llc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the LIQREV profile page.
The generic ingredient in LIQREV is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
The generic ingredient in LIQREV is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Summary for 214952
| Tradename: | LIQREV |
| Applicant: | Cmp Dev Llc |
| Ingredient: | sildenafil citrate |
| Patents: | 4 |
Pharmacology for NDA: 214952
| Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 214952
Suppliers and Packaging for NDA: 214952
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952 | NDA | CMP Pharma, Inc. | 46287-055 | 46287-055-01 | 122 mL in 1 BOTTLE (46287-055-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 10MG BASE/ML | ||||
| Approval Date: | Apr 28, 2023 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Dec 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING | ||||||||
Complete Access Available with Subscription
